Reagentes e instrumentos para imunologia, biologia celular e biologia molecular.
 
> PT-2385 [1672665-49-4]

PT-2385 [1672665-49-4]

Imprimir Imprimir
Please log in

Referência HY-12867-50mg

Tamanho : 50mg

Marca : MedChemExpress

Contactar o distribuidor local :


Telefone : +1 850 650 7790

Description

PT-2385 is a selective HIF-2α inhibitor with a Ki of less than 50 nM[1][2].

IC50 & Target

Kd: <50 nM (HIF-2α)[1]
In Vitro

PT-2385 (PT2385) is a selective antagonist of HIF-2 over HIF-1. PT-2385 is inactive for HIF-1α[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

PT-2385 Related Antibodies

Solvant et solubilité
In Vitro: 

DMSO : ≥ 50 mg/mL (130.43 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.6087 mL 13.0433 mL 26.0865 mL
5 mM 0.5217 mL 2.6087 mL 5.2173 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  5% DMSO    40% PEG300    5% Tween-80    50% Saline

    Solubility: 2.87 mg/mL (7.49 mM); Suspended solution; Need ultrasonic

  • Protocol 2

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (6.52 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Pureté et documentation
Références

Você também pode estar interessado nos seguintes produtos:



Referência
Descrição
Cond.
Price Bef. VAT
HY-12867-10mg
PT-2385 [1672665-49-4]
 10mg 
NB-64-43013-50mg
PT-2385 [1672665-49-4]
 50mg 
HY-12867-5mg
PT-2385 [1672665-49-4]
 5mg